Updates in NRG1+ Tumors

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Results of the phase 2 CRESTONE study have demonstrated the tolerable safety profile and efficacy of seribantumab for the treatment adult patients with metastatic solid or locally advanced tumors harboring the rare NRG1 fusions.

Daniel R. Carrizosa, MD, MS, discusses the design and important efficacy and safety findings from CRESTONE trial evaluating seribantumab and the importance of finding a targeted therapy for patients with solid tumors harboring NRG1 fusions.

Yasir Y. Elamin, MD, discusses NRG1 fusions in solid tumors.

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

Next-generation panel sequencing and a unique algorithm demonstrated the advantage of detecting NRG1 fusions and providing structure information of partners, which could ultimately guide more precise therapeutic options, according to data from a study done in Chinese patients with solid tumors.

Seribantumab was found to produce encouraging overall response rates with acceptable tolerability when used as a monotherapy in patients with solid tumors harboring NRG1 fusions.

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

Zenocutuzumab was found to produce durable responses in patients with previously treated advanced NRG1-positive cancers, with antitumor activity observed across several tumor types, and to have an extremely well tolerated toxicity profile, according to data from a phase 1/2 trial (NCT02912949).

NRG1 fusions, which are often first detected by RNA-based sequencing, confer a more molecularly, pathologically, and clinically diverse subtype of lung cancer compared with historical hypotheses.

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.

John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer.

Stephen Liu, MD, discusses the rationale for examining afatinib in patients with non–small cell lung cancer harboring NRG1 fusions.

January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.